• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ADRB1 Gene Record

  • Summary
  • Interactions
  • Claims
  • ADRB1 153 Druggable Genome

    Alternate Names:

    153
    ADRENOCEPTOR BETA 1
    ADRB1
    ADRB1R
    B1AR
    BETA1AR
    RHR
    109630
    285
    ENSG00000043591
    OTTHUMG00000019079
    P08588
    ADRB1_HUMAN
    BETA-1 ADRENERGIC RECEPTOR
    Beta-1 adrenoceptor
    Beta-1 adrenoreceptor
    BETA-1 ADRENERGIC RECEPTOR (BETA-1 ADRENOCEPTOR) (BETA-1 ADRENORECEPTOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P08588]
    PA38
    Adrenergic receptor beta-1
    T44068
    FNSS2

    Gene Info:

    Target Class Receptors
    Target Subclass GPCR
    Target Subclass Rhodopsin
    Uniprot Status Swiss-Prot
    Interpro Short Name 7TM_GPCR_Rhodpsn
    Human Readable Name DRUGGABLE GENOME
    Uniprot Evidence 1: Evidence at protein level
    Interpro Type Family
    Human Readable Name G PROTEIN COUPLED RECEPTOR
    Interpro Acc IPR000276
    Interpro Name GPCR, rhodopsin-like, 7TM
    Transmembrane Helix Count 7
    Target Main Class Receptors
    Gene Biotype PROTEIN_CODING
    (8 More Sources)

    Gene Categories: Category Details

    G PROTEIN COUPLED RECEPTOR
    DRUGGABLE GENOME

    Publications:

    Abrahamsson, 1989, Characterization of the beta 1-adrenoceptor stimulatory effects of the partial beta 1-agonists acebutolol, xamoterol, H142/08 and H201/70., Eur. J. Pharmacol.
    Fraysse et al., 2005, Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia., Environ. Toxicol. Chem.
    van den Meiracker et al., 1988, Acute and long-term effects of acebutolol on systemic and renal hemodynamics, body fluid volumes, catecholamines, active renin, aldosterone, and lymphocyte beta-adrenoceptor density., J. Cardiovasc. Pharmacol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    el Tayar N et al., 1988, Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists., J Med Chem
    Rau T et al., 2012, Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients., Clin Pharmacol Ther
    Huntgeburth M et al., 2011, The Arg389Gly β1-adrenoceptor gene polymorphism influences the acute effects of β-adrenoceptor blockade on contractility in the human heart., Clin Res Cardiol
    Baudhuin LM et al., 2010, Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure., Am J Cardiol
    Metra M et al., 2010, Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure., Cardiovasc Drugs Ther
    Filigheddu F et al., 2010, Haplotypes of the adrenergic system predict the blood pressure response to beta-blockers in women with essential hypertension., Pharmacogenomics
    Chen L et al., 2007, Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol., Pharmacogenet Genomics
    Lobmeyer MT et al., 2007, Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure., Pharmacogenet Genomics
    Liu J et al., 2006, beta1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension., Clin Pharmacol Ther
    de Groote P et al., 2005, Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure., Pharmacogenet Genomics
    Mialet Perez J et al., 2003, Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure., Nat Med
    Johnson et al., 2003, Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol., Clin. Pharmacol. Ther.
    Sofowora GG et al., 2003, A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade., Clin Pharmacol Ther
    Beitelshees AL et al., 2006, Influence of phenotype and pharmacokinetics on beta-blocker drug target pharmacogenetics., Pharmacogenomics J
    Terra SG et al., 2005, Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy., Pharmacogenet Genomics
    Terra SG et al., 2005, beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure., Clin Pharmacol Ther
    Liu et al., 2003, Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol., Clin. Pharmacol. Ther.
    White HL et al., 2003, An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study., Eur J Heart Fail
    Schäfer et al., 2000, Hypertrophic effect of selective beta(1)-adrenoceptor stimulation on ventricular cardiomyocytes from adult rat., Am. J. Physiol., Cell Physiol.
    Staudt et al., 2003, Beta1-adrenoceptor antibodies induce apoptosis in adult isolated cardiomyocytes., Eur. J. Pharmacol.
    Staudt et al., 2001, beta(1)-Adrenoceptor antibodies induce positive inotropic response in isolated cardiomyocytes., Eur. J. Pharmacol.
    Hoffmann et al., 2004, Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells., Naunyn Schmiedebergs Arch. Pharmacol.
    Chidlow et al., 2000, Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists., Br. J. Pharmacol.
    Brooks et al., Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects., Drugs Aging
    Harris et al., 1994, Correlates of acute exercise-induced ocular hypotension., Invest. Ophthalmol. Vis. Sci.
    Sharif et al., 2001, Levobetaxolol (Betaxon) and other beta-adrenergic antagonists: preclinical pharmacology, IOP-lowering activity and sites of action in human eyes., J Ocul Pharmacol Ther
    Gonzalez et al., 1987, Ocular levobunolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy., Drugs
    Lesar, 1987, Comparison of ophthalmic beta-blocking agents., Clin Pharm
    Hino et al., 1989, Attenuation of ischaemia-induced regional myocardial acidosis by bevantolol, a beta 1-adrenoceptor antagonist, in dogs., Pharmacol. Toxicol.
    Dukes et al., 1985, Cardiovascular effects of bevantolol, a selective beta 1-adrenoceptor antagonist with a novel pharmacological profile., Br. J. Pharmacol.
    Löfdahl et al., Selectivity of bevantolol hydrochloride, a beta 1-adrenoceptor antagonist, in asthmatic patients., Pharmacotherapy
    Horinouchi et al., 2007, Different changes of plasma membrane beta-adrenoceptors in rat heart after chronic administration of propranolol, atenolol and bevantolol., Life Sci.
    Vaughan Williams, 1987, Bevantolol: a beta-1 adrenoceptor antagonist with unique additional actions., J Clin Pharmacol
    Saarnivaara et al., 1984, Effects of practolol and metoprolol on QT interval, heart rate and arterial pressure during induction of anaesthesia., Acta Anaesthesiol Scand
    Abrahamsson, 1986, The beta 1- and beta 2-adrenoceptor stimulatory effects of alprenolol, oxprenolol and pindolol: a study in the isolated right atrium and uterus of the rat., Br. J. Pharmacol.
    Keyriläinen et al., 1978, A comparative study of three beta 1-adrenoreceptor blocking drugs with different degree of intrinsic stimulating activity (metoprolol, practolol and H 87/07) in patients with angina pectoris., Ann. Clin. Res.
    Buxton et al., 1985, Direct analysis of beta-adrenergic receptor subtypes on intact adult ventricular myocytes of the rat., Circ. Res.
    Floreani et al., 2005, In vitro evidence that carteolol is a nonconventional partial agonist of guinea pig cardiac beta1-adrenoceptors: a comparison with xamoterol., J. Pharmacol. Exp. Ther.
    Bruck et al., 2004, Beta 2-adrenoceptor-mediated intrinsic sympathomimetic activity of carteolol: an in vivo study., Naunyn Schmiedebergs Arch. Pharmacol.
    Rouget et al., 2006, Stimulation of the ADRB3 adrenergic receptor induces relaxation of human placental arteries: influence of preeclampsia., Biol. Reprod.
    Lewis et al., 2004, Overexpression of beta 1-adrenoceptors in adult rat ventricular myocytes enhances CGP 12177A cardiostimulation: implications for 'putative' beta 4-adrenoceptor pharmacology., Br. J. Pharmacol.
    Rezmann-Vitti et al., 2004, Site-directed mutagenesis of the rat beta1-adrenoceptor. Involvement of Tyr356 (7.43) in (+/-)cyanopindolol but not (+/-)[125Iodo]cyanopindolol binding., Eur J Med Chem
    Yazawa et al., 2007, Verrucotoxin, a stonefish venom, modulates calcium channel activity in guinea-pig ventricular myocytes., Br. J. Pharmacol.
    Gielen et al., 2006, Nebivolol: a review of its clinical and pharmacological characteristics., Int J Clin Pharmacol Ther
    de Boer et al., 2007, Nebivolol: third-generation beta-blockade., Expert Opin Pharmacother
    Campbell et al., Effects of prolonged administration of oxprenolol on severity of ischaemic arrhythmias, enzyme leakage, infarct size, and intracellular cardiac muscle action potentials., J. Cardiovasc. Pharmacol.
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Lemmer, 1982, [Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author's transl)]., Herz
    Ahlquist, 1976, Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor., Am. Heart J.
    Jurgens et al., 2005, Beta1 adrenergic receptor-mediated enhancement of hippocampal CA3 network activity., J. Pharmacol. Exp. Ther.
    Kobayashi et al., 2005, Beta-arrestin2 enhances beta2-adrenergic receptor-mediated nuclear translocation of ERK., Cell. Signal.
    Sato et al., 2004, Loss of beta-adrenoceptor response in myocytes overexpressing the Na+/Ca(2+)-exchanger., J. Mol. Cell. Cardiol.
    McCrink KA et al., 2016, β<sub>1</sub>-adrenoceptor Arg389Gly polymorphism confers differential β-arrestin-binding tropism in cardiac myocytes., Pharmacogenomics
    Kirshenbaum, 1989, Nonthrombolytic intervention in acute myocardial infarction., Am. J. Cardiol.
    Howie et al., 1990, Esmolol reduces autonomic hypersensitivity and length of seizures induced by electroconvulsive therapy., Anesth. Analg.
    Jahn et al., 1995, Beta 1-adrenoceptor subtype selective antagonism of esmolol and its major metabolite in vitro and in man. Investigations using tricresylphosphate as red blood cell carboxylesterase inhibitor., Arzneimittelforschung
    Jacobs et al., 1988, Esmolol and left ventricular function in the awake dog., Anesthesiology
    Volz-Zang et al., 1994, Esmolol, an ultrashort-acting, selective beta 1-adrenoceptor antagonist: pharmacodynamic and pharmacokinetic properties., Eur. J. Clin. Pharmacol.
    Rosendorff, 1993, Beta-blocking agents with vasodilator activity., J Hypertens Suppl
    Monopoli et al., 1984, Effects of the R, R-isomer of labetalol, SCH 19927, in isolated tissues and in spontaneously hypertensive rats during a repeated treatment., Arch Int Pharmacodyn Ther
    Nakagawa et al., 1981, [Antihypertensive effects of labetalol in three types of hypertensive models of rats (author's transl)]., Nippon Yakurigaku Zasshi
    Sassard et al., 1983, [Comparative effects of an alpha 1 and beta 1-2 blocker (labetalol) and a beta-1 blocker (atenolol) in the hypertensive patient]., J Pharmacol
    van Zwieten, 1993, An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists., Drugs
    Riva et al., 1991, The alpha- and beta-adrenoceptor blocking activities of labetalol and its RR-SR (50:50) stereoisomers., Br. J. Pharmacol.
    Pujos et al., 2009, Comparison of the analysis of beta-blockers by different techniques., J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.
    Turner ST et al., 2003, Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide., Am J Hypertens
    Maitland-van der Zee AH et al., 2005, Demographic, environmental, and genetic predictors of metabolic side effects of hydrochlorothiazide treatment in hypertensive subjects., Am J Hypertens
    Maitland-van der Zee AH et al., 2005, A multilocus approach to the antihypertensive pharmacogenetics of hydrochlorothiazide., Pharmacogenet Genomics
    Rudoy et al., 2007, Betaxolol, a selective beta(1)-adrenergic receptor antagonist, diminishes anxiety-like behavior during early withdrawal from chronic cocaine administration in rats., Prog. Neuropsychopharmacol. Biol. Psychiatry
    Satoh et al., 1990, Effects of betaxolol on cardiohemodynamics and coronary circulation in anesthetized dogs: comparison with atenolol and propranolol., Jpn. J. Pharmacol.
    McLean et al., 2002, Generation and analysis of constitutively active and physically destabilized mutants of the human beta(1)-adrenoceptor., Mol. Pharmacol.
    Geese WJ et al., 2008, Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists., Pharmacogenet Genomics
    Wang et al., 1996, (--)-Timolol is a more potent antagonist of the positive inotropic effects of (--)-adrenaline than of those of (--)-noradrenaline in human atrium., Br J Clin Pharmacol
    Nieminen et al., 2005, Polymorphisms of genes CYP2D6, ADRB1 and GNAS1 in pharmacokinetics and systemic effects of ophthalmic timolol. A pilot study., Eur. J. Clin. Pharmacol.
    Bhattacharyya et al., 2002, (-)-Isoproterenol modulation of maxi-K(+) channel in nonpigmented ciliary epithelial cells through a G-protein gated pathway., Curr. Eye Res.
    Hirooka et al., 2000, Suppressive actions of betaxolol on ionic currents in retinal ganglion cells may explain its neuroprotective effects., Exp. Eye Res.
    Varma et al., 1999, Inverse agonist activities of beta-adrenoceptor antagonists in rat myocardium., Br. J. Pharmacol.
    Zimmerman et al., The beta-adrenergic blocking agents and the treatment of glaucoma., Surv Ophthalmol
    Varma, 1999, Ligand-independent negative chronotropic responses of rat and mouse right atria to beta-adrenoceptor antagonists., Can. J. Physiol. Pharmacol.
    Wheeldon et al., 1994, The effects of lower than conventional doses of oral nadolol on relative beta 1/beta 2-adrenoceptor blockade., Br J Clin Pharmacol
    Wheeldon et al., 1994, Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man., Br J Clin Pharmacol
    Koshiji et al., 1992, A comparison of guanfacine, bunazosin, atenolol and nadolol on blood pressure and plasma noradrenaline responses to cold pressor testing., Clin. Exp. Pharmacol. Physiol.
    Watkins et al., 1996, Loss of [125I]-pindolol binding to beta-adrenoceptors on rat nodose ganglion after chronic isoprenaline treatment., J. Auton. Nerv. Syst.
    Berendsen et al., 1990, Antagonism of 8-OH-DPAT-induced behaviour in rats., Eur. J. Pharmacol.
    Brodde et al., 1988, Chronic beta-adrenoceptor antagonist treatment modulates human cardiac and vascular beta-adrenoceptor density in a subtype-selective fashion., J Hypertens Suppl
    Joseph et al., 2003, Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors., Naunyn Schmiedebergs Arch. Pharmacol.
    Doggrell, 1991, Effects of (+/-)- (+)- and (-)-metoprolol, (+/-)- (+)- and (-)-pindolol, (+/-)-mepindolol and (+/-)-bopindolol on the rat left atria and portal vein., Gen. Pharmacol.
    O'Shaughnessy KM et al., 2000, The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta-blockade in hypertensive subjects., Clin Sci (Lond)
    Alberti et al., 1997, Mechanism and pressor relevance of the short-term cardiovascular and renin excitatory actions of the selective A2A-adenosine receptor agonists., J. Cardiovasc. Pharmacol.
    Brown et al., 2002, Dietary Mg(2+) supplementation restores impaired vasoactive responses in isolated rat aorta induced by chronic ethanol consumption., Eur. J. Pharmacol.
    Rydén M et al., 2001, The Arg 389 Gly beta1-adrenergic receptor gene polymorphism and human fat cell lipolysis., Int J Obes Relat Metab Disord
    Bruck et al., 2005, The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity., J. Am. Coll. Cardiol.
    La Rosée et al., 2004, The Arg389Gly beta1-adrenoceptor gene polymorphism determines contractile response to catecholamines., Pharmacogenetics
    Junker et al., 2002, Stimulation of beta-adrenoceptors activates astrocytes and provides neuroprotection., Eur. J. Pharmacol.
    Raddatz et al., 2006, Dobutamine improves liver function after hemorrhagic shock through induction of heme oxygenase-1., Am. J. Respir. Crit. Care Med.
    Doggrell et al., 2002, Present and future pharmacotherapy for heart failure., Expert Opin Pharmacother
    Disatnik MH et al., 1991, Regulation of beta-adrenoceptors by thyroid hormone and amiodarone in rat myocardiac cells in culture., Biochem Pharmacol
    Drvota V et al., 1999, The effect of amiodarone on the beta-adrenergic receptor is due to a downregulation of receptor protein and not to a receptor-ligand interaction., Biochem Biophys Res Commun
    Kim KM et al., 2012, Pharmacogenetics and healthcare outcomes in patients with chronic heart failure., Eur J Clin Pharmacol
    Arai et al., 2003, Beta-adrenergic receptor agonists and antagonists counteract LPS-induced neuronal death in retinal cultures by different mechanisms., Brain Res.
    Drímal et al., 1987, External transport of beta-adrenergic binding sites in ischemic myocardium., Gen. Physiol. Biophys.
    Bilcíková et al., 1987, The action of adrenoceptor agonists and antagonists on the guinea pig and dog trachea., Gen. Physiol. Biophys.
    El-Armouche et al., 2009, Beta-adrenergic stimulation and myocardial function in the failing heart., Heart Fail Rev
    Mersmann, 1998, Overview of the effects of beta-adrenergic receptor agonists on animal growth including mechanisms of action., J. Anim. Sci.
    Gilsbach et al., 2008, Presynaptic metabotropic receptors for acetylcholine and adrenaline/noradrenaline., Handb Exp Pharmacol
    Nichols et al., 1989, The interaction of the enantiomers of carvedilol with alpha 1- and beta 1-adrenoceptors., Chirality
    Nichols et al., 1989, In vitro pharmacologic profile of the novel beta-adrenoceptor antagonist and vasodilator, carvedilol., Pharmacology
    de Mey et al., 1994, Dose-effect and pharmacokinetic-pharmacodynamic relationships of the beta 1-adrenergic receptor blocking properties of various doses of carvedilol in healthy humans., Clin. Pharmacol. Ther.
    Nichols et al., 1991, Studies on the mechanism of arterial vasodilation produced by the novel antihypertensive agent, carvedilol., Fundam Clin Pharmacol
    Mudunkotuwa et al., 1996, Desipramine administration in the olfactory bulbectomized rat: changes in brain beta-adrenoceptor and 5-HT2A binding sites and their relationship to behaviour., Br. J. Pharmacol.
    Matsumoto et al., 1994, Beta 2- but not beta 1-adrenoceptors are involved in desipramine enhancement of aggressive behavior in long-term isolated mice., Pharmacol. Biochem. Behav.
    Sapena et al., 1996, Desipramine treatment differently down-regulates beta-adrenoceptors of freshly isolated neurons and astrocytes., Eur. J. Pharmacol.
    Samnick et al., 2004, Technetium-99m labeled 1-(4-fluorobenzyl)-4-(2-mercapto-2-methyl-4-azapentyl)-4-(2-mercapto-2-methylpropylamino)-piperidine and iodine-123 metaiodobenzylguanidine for studying cardiac adrenergic function: a comparison of the uptake characteristics in vascular smooth muscle cells and neonatal cardiac myocytes, and an investigation in rats., Nucl. Med. Biol.
    Bürgi et al., 2003, Antidepressant-induced switch of beta 1-adrenoceptor trafficking as a mechanism for drug action., J. Biol. Chem.
    Brouri et al., 2004, Blockade of beta 1- and desensitization of beta 2-adrenoceptors reduce isoprenaline-induced cardiac fibrosis., Eur. J. Pharmacol.
    Breed et al., 1992, Quality of life perception during antihypertensive treatment: a comparative study of bisoprolol and enalapril., J. Cardiovasc. Pharmacol.
    Mauz et al., 1990, Beta-adrenoceptor-binding studies of the cardioselective beta blockers bisoprolol, H-I 42 BS, and HX-CH 44 BS to heart membranes and intact ventricular myocytes of adult rats: two beta 1-binding sites for bisoprolol., J. Cardiovasc. Pharmacol.
    Lipworth et al., 1991, A dose-ranging study to evaluate the beta 1-adrenoceptor selectivity of bisoprolol., Eur. J. Clin. Pharmacol.
    Doze et al., 2002, Synthesis and evaluation of radiolabeled antagonists for imaging of beta-adrenoceptors in the brain with PET., Neurochem. Int.
    Venter et al., 1982, Ethnic differences in beta-1-adrenoceptor sensitivity., S. Afr. Med. J.
    Sánchez, 1993, Effect of serotonergic drugs on footshock-induced ultrasonic vocalization in adult male rats., Behav Pharmacol
    Frishman et al., 1990, Penbutolol and carteolol: two new beta-adrenergic blockers with partial agonism., J Clin Pharmacol
    Rodrigues et al., 2006, Peripheral sympathetic component of the temporomandibular joint inflammatory pain in rats., J Pain
    Terra et al., 2005, Association between beta-adrenergic receptor polymorphisms and their G-protein-coupled receptors with body mass index and obesity in women: a report from the NHLBI-sponsored WISE study., Int J Obes (Lond)
    Muszkat, 2007, Interethnic differences in drug response: the contribution of genetic variability in beta adrenergic receptor and cytochrome P4502C9., Clin. Pharmacol. Ther.
    Burniston et al., 2006, Relative myotoxic and haemodynamic effects of the beta-agonists fenoterol and clenbuterol measured in conscious unrestrained rats., Exp. Physiol.
    Molenaar P et al., 2002, Conservation of the cardiostimulant effects of (-)-norepinephrine across Ser49Gly and Gly389Arg beta(1)-adrenergic receptor polymorphisms in human right atrium in vitro., J Am Coll Cardiol
    Ozakca et al., 2007, Role of beta-3-adrenoceptor in catecholamine-induced relaxations in gastric fundus from control and diabetic rats., Pharmacology
    Leineweber et al., 2007, In patients chronically treated with metoprolol, the demand of inotropic catecholamine support after coronary artery bypass grafting is determined by the Arg389Gly-beta 1-adrenoceptor polymorphism., Naunyn Schmiedebergs Arch. Pharmacol.
    Strosberg AD, 1993, Structure, function, and regulation of adrenergic receptors., Protein Sci
    Khasar SG et al., 1999, Epinephrine produces a beta-adrenergic receptor-mediated mechanical hyperalgesia and in vitro sensitization of rat nociceptors., J Neurophysiol
    Abou-Mohamed et al., 1996, Characterization of the adrenergic activity of arbutamine, a novel agent for pharmacological stress testing., Cardiovasc Drugs Ther
    Doggrell, 1993, The effects of (+/-)-, (+)-, and (-)-atenolol, sotalol, and amosulalol on the rat left atria and portal vein., Chirality
    Juberg et al., 1985, Beta 1- and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart., Naunyn Schmiedebergs Arch. Pharmacol.
    Yalcin et al., 2009, beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain., Ann. Neurol.
    Joseph et al., 2004, Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers., Naunyn Schmiedebergs Arch. Pharmacol.
    Lowe et al., 2002, Comparison of the affinity of beta-blockers for two states of the beta 1-adrenoceptor in ferret ventricular myocardium., Br. J. Pharmacol.
    De Ponti et al., 1995, Inhibitory effects of SR 58611A on canine colonic motility: evidence for a role of beta 3-adrenoceptors., Br. J. Pharmacol.
    Surman et al., 1993, Alprenolol and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the beta 1-adrenoceptors of rat left atria., J. Cardiovasc. Pharmacol.
    Im et al., 1988, Interactions of pure beta gamma-subunits of G-proteins with purified beta 1-adrenoceptor., FEBS Lett.
    Brahmadevara et al., 2003, Evidence against beta 3-adrenoceptors or low affinity state of beta 1-adrenoceptors mediating relaxation in rat isolated aorta., Br. J. Pharmacol.
    Zelaszczyk et al., 2009, Four close bupranolol analogues are antagonists at the low-affinity state of beta1-adrenoceptors., J. Physiol. Pharmacol.
    Dale et al., 2007, Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter., Ann Pharmacother
    Heijman J et al., 2013, Pleiotropic effects of antiarrhythmic agents: dronedarone in the treatment of atrial fibrillation., Clin Med Insights Cardiol
    Bacaner et al., 1982, Antiarrhythmic, antifibrillatory, and hemodynamic actions of bethanidine sulfate: an orally effective analog of bretylium for suppression of ventricular tachyarrhythmias., Am. J. Cardiol.
    Hart et al., 1981, Withdrawal syndromes and the cessation of antihypertensive therapy., Arch. Intern. Med.
    Yao et al., 2008, Effects of the antioxidative beta-blocker celiprolol on endothelial progenitor cells in hypertensive rats., Am. J. Hypertens.
    Chen et al., 2007, Celiprolol, a selective beta1-blocker, reduces the infarct size through production of nitric oxide in a rabbit model of myocardial infarction., Circ. J.
    Hayashi et al., 2007, beta1 antagonist and beta2 agonist, celiprolol, restores the impaired endothelial dependent and independent responses and decreased TNFalpha in rat with type II diabetes., Life Sci.
  • BETAXOLOL   ADRB1

    Interaction Score: 7.45

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    2903243 2891463 17513029 11752352 2077180 12181453


    Sources:
    DTC TdgClinicalTrial TEND TTD

  • PRACTOLOL   ADRB1

    Interaction Score: 7.45

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    2903243 11752352 6524278 2871880 30388 2857116


    Sources:
    DTC TdgClinicalTrial TEND TTD

  • ESMOLOL   ADRB1

    Interaction Score: 6.7

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    2568748 1975995 7612051 2894187 7957532 11752352


    Sources:
    TdgClinicalTrial TEND TTD

  • BISOPROLOL   ADRB1

    Interaction Score: 4.84

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    15861037 16325050 14757145 1280737 1691366 11752352 1676675 2903243


    Sources:
    DTC TdgClinicalTrial TEND PharmGKB TTD

  • BUCINDOLOL   ADRB1

    Interaction Score: 4.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name bucindolol hydrochloride,Gencaro
    Novel drug target Established target

    PMIDs:
    22617224 21311897 20643254 20352314 20235788 18075464 17496726 16815314 15864115 15861037 15735607 14534524 14502278 12921807 12844134 12709726


    Sources:
    TdgClinicalTrial PharmGKB TTD

  • ARBUTAMINE   ADRB1

    Interaction Score: 4.47

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    17016423 17139284 8723169


    Sources:
    TdgClinicalTrial TEND TTD

  • ALPRENOLOL   ADRB1

    Interaction Score: 3.72

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    7606348 7678677 2828119 11752352 12522078 10433496 2903243


    Sources:
    DTC TdgClinicalTrial TEND

  • ACEBUTOLOL   ADRB1

    Interaction Score: 3.72

    Interaction Types & Directionality:
    partial agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    2568935 16268148 2453744 11752352 2903243


    Sources:
    DTC TdgClinicalTrial TEND PharmGKB TTD

  • OXPRENOLOL   ADRB1

    Interaction Score: 3.35

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    2871880 11752352 6202960 17016423 17139284 6124492


    Sources:
    TdgClinicalTrial TEND TTD

  • CARTEOLOL   ADRB1

    Interaction Score: 3.35

    Interaction Types & Directionality:
    partial agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    16160085 10864881 15526107 11752352 2903243


    Sources:
    DTC TdgClinicalTrial TEND TTD

  • LEVOBUNOLOL   ADRB1

    Interaction Score: 3.35

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    10864881 1351412 7928182 11572462 2892662 2891463


    Sources:
    TdgClinicalTrial TEND TTD

  • TIMOLOL   ADRB1

    Interaction Score: 3.23

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor antagonist
    Direct Interaction yes
    Trial Name brimonidine tartrate/timolol maleate,Combigan

    PMIDs:
    8864321 16315032 12221524 11752352 10870519 10433496 2903243


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • PINDOLOL   ADRB1

    Interaction Score: 2.98

    Interaction Types & Directionality:
    partial agonist (activating)
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target
    Mechanism of Interaction Beta-1 adrenergic receptor partial agonist

    PMIDs:
    8884690 2148726 2907348 14608456 11752352 1687398 2903243


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND TTD

  • PENBUTOLOL   ADRB1

    Interaction Score: 2.61

    Interaction Types & Directionality:
    partial agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    11738481 6755764 11224195 2189902


    Sources:
    TdgClinicalTrial TEND TTD

  • BEVANTOLOL   ADRB1

    Interaction Score: 2.61

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    2568629 2858236 6148733 17628611 2888789


    Sources:
    TdgClinicalTrial TEND

  • METOPROLOL   ADRB1

    Interaction Score: 2.51

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name metoprolol succinate,Toprol-XL
    Novel drug target Established target
    Trial Name -

    PMIDs:
    22617224 21311897 20643254 20352314 20235788 18075464 17496726 16815314 15861037 14502278 12844134 12709726 16402084 15864115 15735607 14534524 12921807 2903243 10913016 11752352 12679135 11448474


    Sources:
    DTC TdgClinicalTrial TEND PharmGKB TTD

  • DOBUTAMINE   ADRB1

    Interaction Score: 2.48

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    11753577 16325050 15564877 12098582 16627864 11752352


    Sources:
    TdgClinicalTrial TEND PharmGKB TTD

  • NADOLOL   ADRB1

    Interaction Score: 2.23

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor antagonist
    Direct Interaction yes
    Trial Name -

    PMIDs:
    10606440 7981009 7912539 1354084 11752352 10433496 2903243


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND TTD

  • BUFURALOL   ADRB1

    Interaction Score: 2.23

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    2903243 37605


    Sources:
    DTC

  • NEBIVOLOL   ADRB1

    Interaction Score: 2.23

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name nebivolol ,Bystolic

    PMIDs:
    16961165 17661735 11752352


    Sources:
    TdgClinicalTrial TEND TTD

  • METIPRANOLOL   ADRB1

    Interaction Score: 1.99

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    12967722 17016423 17139284 2895037 2885244


    Sources:
    TdgClinicalTrial TEND TTD

  • CELIPROLOL   ADRB1

    Interaction Score: 1.86

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    2903243 18636069 17384462 17141277


    Sources:
    DTC

  • ISOETHARINE   ADRB1

    Interaction Score: 1.3

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    17157779 15917856 17329986 17628611 16973691


    Sources:
    TdgClinicalTrial TEND

  • BUPRANOLOL   ADRB1

    Interaction Score: 1.12

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    2903243 19439807


    Sources:
    DTC

  • CARVEDILOL   ADRB1

    Interaction Score: 1.03

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name carvedilol,Coreg
    Novel drug target Established target
    Mechanism of Interaction Adrenergic receptor beta antagonist

    PMIDs:
    27643874 22617224 21311897 20643254 20352314 20235788 18075464 17496726 16815314 15864115 15861037 15735607 14534524 14502278 12921807 12844134 12709726 2577144 2575762 7908256 1712335


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB

  • METOPROLOL SUCCINATE   ADRB1

    Interaction Score: 0.74

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • BISOPROLOL FUMARATE   ADRB1

    Interaction Score: 0.74

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Beta-1 adrenergic receptor antagonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • BRETYLIUM   ADRB1

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • ACEBUTOLOL HYDROCHLORIDE   ADRB1

    Interaction Score: 0.74

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LEVOBETAXOLOL HYDROCHLORIDE   ADRB1

    Interaction Score: 0.74

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ANISODAMINE   ADRB1

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • BUNOLOL   ADRB1

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2903243


    Sources:
    DTC

  • BUNITROLOL   ADRB1

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2903243


    Sources:
    DTC

  • DICHLOROISOPROTERENOL   ADRB1

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2903243


    Sources:
    DTC

  • LEVOBETAXOLOL   ADRB1

    Interaction Score: 0.74

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • SOTALOL   ADRB1

    Interaction Score: 0.67

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    8095397 2865685 19259968 11752352 15060759 11815381 2903243


    Sources:
    DTC TTD

  • ATENOLOL   ADRB1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor antagonist
    Direct Interaction yes
    Trial Name -

    PMIDs:
    2903243 22617224 21311897 20643254 20352314 20235788 18075464 17496726 16815314 15864115 15861037 15735607 14534524 14502278 12921807 12844134 11787477 12709726 9300315 10913016 12065078 17628611 11752352


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • LABETALOL   ADRB1

    Interaction Score: 0.62

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -

    PMIDs:
    8104240 6151824 7286847 6355664 7684671 1687367 19879818 11752352


    Sources:
    TdgClinicalTrial TEND

  • PROPRANOLOL   ADRB1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name VT-122
    Novel drug target Established target

    PMIDs:
    16177222 17628611 14757703 11752352 15236843 17572694 2903243


    Sources:
    DTC TdgClinicalTrial TEND TTD

  • MEPINDOLOL   ADRB1

    Interaction Score: 0.5

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2903243


    Sources:
    DTC

  • TERTATOLOL   ADRB1

    Interaction Score: 0.5

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2903243


    Sources:
    DTC

  • ESMOLOL HYDROCHLORIDE   ADRB1

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • METIPRANOLOL HYDROCHLORIDE   ADRB1

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LEVOBUNOLOL HYDROCHLORIDE   ADRB1

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • TIMOLOL MALEATE   ADRB1

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DIPIVEFRIN   ADRB1

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • BETHANIDINE   ADRB1

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:

    PMIDs:
    6812406 6114720 11752352


    Sources:
    TTD

  • DRONEDARONE   ADRB1

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    17389667 23997577


    Sources:
    TdgClinicalTrial TEND

  • CHEMBL111201   ADRB1

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • OXPRENOLOL HYDROCHLORIDE   ADRB1

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • BETAXOLOL HYDROCHLORIDE   ADRB1

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DROXIDOPA   ADRB1

    Interaction Score: 0.37

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Adrenergic receptor agonist

    PMIDs:
    19110970 9464897 18064417


    Sources:
    ChemblInteractions

  • NEBIVOLOL HYDROCHLORIDE   ADRB1

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • PENBUTOLOL SULFATE   ADRB1

    Interaction Score: 0.37

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • SALMETEROL   ADRB1

    Interaction Score: 0.37

    Interaction Types & Directionality:
    inverse agonist (inhibitory)

    Interaction Info:

    PMIDs:
    14730417


    Sources:
    DTC

  • DESIPRAMINE   ADRB1

    Interaction Score: 0.35

    Interaction Types & Directionality:
    other/unknown

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    8730743 7816863 8741184 15093822 12393876


    Sources:
    TdgClinicalTrial TEND

  • NOREPINEPHRINE   ADRB1

    Interaction Score: 0.29

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    2903243 19110970 9464897 18064417 11752352 12383575


    Sources:
    DTC PharmGKB TTD

  • ISOPROTERENOL   ADRB1

    Interaction Score: 0.27

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name -
    Novel drug target Established target

    PMIDs:
    10722 11752352 15908512 16038799 14734046 27643874


    Sources:
    TdgClinicalTrial TEND PharmGKB TTD

  • CARTEOLOL HYDROCHLORIDE   ADRB1

    Interaction Score: 0.25

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Adrenergic receptor beta antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LY377604   ADRB1

    Interaction Score: 0.25

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • PROPRANOLOL HYDROCHLORIDE   ADRB1

    Interaction Score: 0.25

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • EPINEPHRINE   ADRB1

    Interaction Score: 0.25

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Novel drug target Established target
    Trial Name transdermal lidocaine/epinephrine patch,Lidosite
    Mechanism of Interaction Adrenergic receptor agonist

    PMIDs:
    17622774 11752352 17541557 8401205 10085337


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • MURAGLITAZAR   ADRB1

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18794727


    Sources:
    PharmGKB

  • BUDIODARONE   ADRB1

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name budiodarone, ATI-2042
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • SOTALOL HYDROCHLORIDE   ADRB1

    Interaction Score: 0.19

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DOBUTAMINE HYDROCHLORIDE   ADRB1

    Interaction Score: 0.19

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • INDACATEROL   ADRB1

    Interaction Score: 0.19

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • AMIODARONE   ADRB1

    Interaction Score: 0.18

    Interaction Types & Directionality:
    negative modulator (inhibitory)
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name amiodarone HCl,Amio-Aqueous IV
    Novel drug target Established target

    PMIDs:
    12083991 1672592 10049740


    Sources:
    TdgClinicalTrial TEND

  • CARVEDILOL PHOSPHATE   ADRB1

    Interaction Score: 0.15

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Adrenergic receptor beta antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • ISOPROTERENOL HYDROCHLORIDE   ADRB1

    Interaction Score: 0.15

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Adrenergic receptor beta agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • MEPHENTERMINE SULFATE   ADRB1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Adrenergic receptor agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DIPIVEFRIN HYDROCHLORIDE   ADRB1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Adrenergic receptor agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • LABETALOL HYDROCHLORIDE   ADRB1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Adrenergic receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • HYDROXYAMPHETAMINE HYDROBROMIDE   ADRB1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Adrenergic receptor agonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • HYDROCHLOROTHIAZIDE   ADRB1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14553962 16109321 15864129


    Sources:
    PharmGKB

  • SPIRONOLACTONE   ADRB1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22543981


    Sources:
    PharmGKB

  • DOPAMINE HYDROCHLORIDE   ADRB1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • NOREPINEPHRINE BITARTRATE   ADRB1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Mechanism of Interaction Adrenergic receptor agonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • PROPAFENONE HYDROCHLORIDE   ADRB1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Beta-1 adrenergic receptor antagonist
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • EPINEPHRINE BITARTRATE   ADRB1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Adrenergic receptor agonist

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DIGOXIN   ADRB1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22543981


    Sources:
    PharmGKB

  • ZIPRASIDONE   ADRB1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TEND

  • DOPAMINE   ADRB1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • Ensembl: ENSG00000043591

    • Version: 101_38

    Alternate Names:
    ADRB1 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TdgClinicalTrial: P08588

    • Version: January-2014

    Alternate Names:
    ADRB1 Gene Symbol

    Gene Info:
    Target Class Receptors
    Target Subclass GPCR
    Target Subclass Rhodopsin

    Publications:

  • HopkinsGroom: P08588

    • Version: 11-September-2012

    Alternate Names:
    ADRB1 Uniprot Gene Name
    BETA-1 ADRENERGIC RECEPTOR Uniprot Protein Name
    P08588 Uniprot Accession

    Gene Info:
    Uniprot Status Swiss-Prot
    Interpro Short Name 7TM_GPCR_Rhodpsn
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME

    Publications:

  • RussLampel: ENSG00000043591

    • Version: 26-July-2011

    Alternate Names:
    ENSG00000043591 Ensembl Gene Id
    ADRB1 Display Id
    BETA-1 ADRENERGIC RECEPTOR (BETA-1 ADRENOCEPTOR) (BETA-1 ADRENORECEPTOR). [SOURCE:UNIPROT/SWISSPROT;ACC:P08588] Description

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • TEND: P08588

    • Version: 01-August-2011

    Alternate Names:
    ADRB1 Gene Symbol
    P08588 Uniprot Accession
    ADRB1_HUMAN Uniprot Id

    Gene Info:
    Transmembrane Helix Count 7
    Target Main Class Receptors
    Target Subclass Rhodopsin

    Publications:

  • PharmGKB: ADRB1

    • Version: 18-August-2020

    Alternate Names:
    PA38 PharmGKB ID

    Gene Info:

    Publications:
    Terra SG et al., 2005, Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy., Pharmacogenet Genomics
    Baudhuin LM et al., 2010, Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure., Am J Cardiol
    de Groote P et al., 2005, Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure., Pharmacogenet Genomics

  • TTD: Adrenergic receptor beta-1

    • Version: 2020.06.01

    Alternate Names:
    ADRB1 TTD Gene Abbreviation
    T44068 TTD Target ID

    Gene Info:

    Publications:
    Aggerbeck et al., 1979, N-Aralkyl substitution increases the affinity of adrenergic drugs for the alpha-adrenoceptor in rat liver., Br. J. Pharmacol.

  • DTC: ADRB1

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    el Tayar N et al., 1988, Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists., J Med Chem

  • HingoraniCasas: ENSG00000043591

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000043591 Gene Symbol
    ADRB1 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • ChemblInteractions: ADRB1R

    • Version: chembl_23

    Alternate Names:
    B1AR GENE_SYMBOL
    ADRB1 GENE_SYMBOL
    Beta-1 adrenergic receptor UNIPROT

    Gene Info:

    Publications:

  • GO: ADRB1

    • Version: 01-February-2022

    Alternate Names:
    ADRB1R GO Gene Synonym
    B1AR GO Gene Synonym

    Gene Info:

    Gene Categories:
    G PROTEIN COUPLED RECEPTOR

    Publications:

  • dGene: ADRB1

    • Version: 27-Jun-2013

    Alternate Names:
    153 Gene ID
    ADRB1R dGene Synonym
    B1AR dGene Synonym

    Gene Info:

    Gene Categories:
    G PROTEIN COUPLED RECEPTOR

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21